Has Mehmet Copur, MD received payments from drug or device companies?

Yes. Drug and device makers reported $49,011 in general payments to Mehmet Copur, MD across 709 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mehmet Copur, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mehmet Copur, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mehmet Copur, MD

Hematology & Oncology · Grand Island, NENPI 1871517433

Payments from drug & device makers

$49,011in general payments, 2019–2025

Across 709 payments — averaging $69.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$10K
Karyopharm Therapeutics Inc.$10K
Amgen$6K
Merck$5K
Array Biopharma Inc$3K
Takeda Pharmaceuticals U.S.A., Inc.$2K
plus $14K from 54 others

$1,837in research payments, 2019–2025

Across 2 payments — averaging $918.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$1K
F. Hoffmann-la Roche AG$478

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	15	$9,859
Karyopharm Therapeutics Inc.	11	$9,611
Amgen	28	$6,146
Merck	42	$4,845
Array Biopharma Inc	15	$2,581
Takeda Pharmaceuticals U.S.A., Inc.	12	$2,337
Gilead(2 entities)	22	$1,719
Pfizer	65	$1,054
Seagen Inc.	42	$1,040
Pharmacyclics LLC, An Abbvie Company	18	$1,037
E.r. Squibb & Sons, L.L.C.	58	$870
Novartis	44	$685
AstraZeneca(2 entities)	23	$609
Astellas Pharma US Inc	19	$595
Daiichi Sankyo Inc.	39	$568
Johnson & Johnson(2 entities)	33	$550
Deciphera Pharmaceuticals Inc.	2	$422
AbbVie	18	$380
Eisai Inc.	21	$365
AVEO Pharmaceuticals, Inc.	11	$315
Pharmacosmos Therapeutics Inc.	7	$309
Bristol Myers Squibb	18	$301
Genentech USA, Inc.	19	$276
Exelixis Inc.	8	$234
Lilly USA, LLC	13	$216
Sanofi-aventis U.S. LLC	2	$200
Tersera Therapeutics LLC	7	$192
Servier Pharmaceuticals LLC	7	$132
Sanofi	8	$130
Recordati_rare_diseases_inc.	2	$109
Regeneron Healthcare Solutions, Inc.	6	$106
Bayer	6	$103
GSK	7	$102
Mirati Therapeutics, Inc.	5	$93
Adaptive Biotechnologies Corporation	5	$92
Jazz Pharmaceuticals Inc.	6	$88
Pharmaessentia USA Corporation	4	$69
Stemline Therapeutics Inc.	3	$64
Taiho Oncology, Inc.	3	$60
Foundation Medicine, Inc.	3	$46
Dendreon Pharmaceuticals LLC	1	$40
Acrotech Biopharma Inc.	3	$38
Octapharma USA, Inc.	2	$37
Blueprint Medicines Corporation	2	$34
Boehringer Ingelheim	2	$33
Puma Biotechnology, Inc.	2	$33
Novocure Inc.	3	$33
Agios Pharmaceuticals, Inc.	2	$30
Medtronic	2	$30
Immunogen, Inc.	1	$24
Syndax Pharmaceuticals, Inc.	1	$17
CTI Biopharma Corp.	1	$16
G1 Therapeutics, Inc.	1	$16
Kyowa Kirin, Inc.	1	$15
ADC Therapeutics America, Inc.	1	$15
Dova Pharmaceuticals	1	$15
Iovance Biotherapeutics, Inc.	1	$14
AMAG Pharmaceuticals, Inc.	1	$13
Blue Earth Diagnostics	1	$13
Myriad Genetic Laboratories, Inc.	1	$12

How this compares

$49,011 in reported general payments places this provider in the 50th percentile of 73 hematology & oncology providers in Nebraska.

See all hematology & oncology providers in Nebraska →

Medicare billing

Part B allowed, 2024

$104,691

Medicare patients

420

Services billed

1,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Grand Island

Ryan RamaekersGrand Island$1.3M
Sarah CreamerGrand Island$130K
Luke NordquistOmaha$29.3M
Ralph HaukeOmaha$12.1M
Margaret BlockOmaha$8.3M
Kailash MosalpuriaLincoln$4.2M
Stefano TarantoloOmaha$3.7M
Julie VoseOmaha$3.5M
Debora BrunoHastings$3M
Robert BociekOmaha$3M

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →